Pulmonary delivery of inhalable nanoparticles: Dry powder inhalers

Therapeutic Delivery

Volumn 2, Issue 10, 2011, Pages 1313-1324

  Al Hallak, MHD Kamal ^a,b   Sarfraz, Muhammad Khan ^a,c   Azarmi, Shirzad ^a,d   Roa, Wilson H ^a   Finlay, Warren H ^a   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^c THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; BUDESONIDE; CHITOSAN; CIPROFLOXACIN; DIATRIZOATE; DIPHTHERIA TOXOID CRM197; EXCIPIENT; GELATIN; HEPATITIS B SURFACE ANTIGEN; HONOKIOL; INSULIN; LEUCINE; MACROGOL; MANNITOL; NANOAGGREGATE; NANOCOMPOSITE; NANOMATERIAL; NANOPARTICLE; NIFEDIPINE; PACLITAXEL; POLYCAPROLACTONE; POLYGLACTIN; POLYVINYL ALCOHOL; PRANLUKAST; RIFAMPICIN; SODIUM CHLORIDE; SOLID LIPID NANOPARTICLE; THYMOPENTIN; TROJAN PARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ASTHMA; CHEMICAL PROCEDURES; COLLOID; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; FLOCCULATION; HUMAN; LUNG CANCER; METERED DOSE INHALER; NEBULIZER; NONHUMAN; POWDER INHALER; PRIORITY JOURNAL; REVIEW; SPRAY DRYING; SPRAY FREEZE DRYING; ULTRASOUND;

EID: 80054115937     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.100     Document Type: Review

References (82)

1. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008)
2. Fukami T, Ishii T, Io T et al. Nanoparticle processing in the solid state dramatically increases the cell membrane permeation of a cholesterol-lowering drug, probucol. Mol. Pharm. 6(3), 1029-1035 (2009)
3. Khan JA, Kainthan RK, Ganguli M, Kizhakkedathu JN, Singh Y, Maiti S. Water soluble nanoparticles from PEG-based cationic hyperbranched polymer and RNA that protect RNA from enzymatic degradation. Biomacromolecules 7(5), 1386-1388 (2006) (Pubitemid 43811192)
4. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 317(3), 1372-1381 (2006) (Pubitemid 43764144)
5. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56(11), 1649-1659 (2004) (Pubitemid 39177694)
6. Gipps EM, Groscurth P, Kreuter J, Speiser PP. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice over extended times and after repeated injection. J. Pharm. Sci. 77(3), 208-209 (1988)
7. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001) (Pubitemid 32476118)
8. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J. Pharm. Sci. 85(5), 530-536 (1996) (Pubitemid 26153217)
9. Cosco D, Celia C, Cilurzo F, Trapasso E, Paolino D. Colloidal carriers for the enhanced delivery through the skin. Expert Opin. Drug Deliv. 5(7), 737-755 (2008)
10. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60(8), 863-875 (2008)
11. Al-Hallak KM, Azarmi S, Anwar-Mohamed A, Roa WH, Lobenberg R. Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy? Eur. J. Pharm. Biopharm. 76(1), 112-119 (2010)
12. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm. Res. 24(3), 411-437 (2007) (Pubitemid 46295160)
13. Dailey LA, Schmehl T, Gessler T et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control. Release 86(1), 131-144 (2003) (Pubitemid 35461980)
14. Shrewsbury SB, Bosco AP, Uster PS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int. J. Pharm. 365(1-2), 12-17 (2009)
15. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller Gk, Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug-delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52(6), 981-986 (2003) (Pubitemid 38008419)
16. Ostrander KD, Bosch HW, Bondanza DM. An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 48(3), 207-215 (1999) (Pubitemid 29509787)
17. Rance RW. Studies of the factors controlling the action of hair sprays: III. The influence of particle velocity and diameter on the capture of particles by arrays of hair fiber J. Soc. Cosm. Chem. 25, 545-561 (1974)
18. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneski M. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101, 1-13 (1994)
19. Crompton GK. Dry powder inhalers: advantages and limitations. J. Aerosol Med. 4(3), 151-156 (1991)
20. Finlay WH. The Mechanics of Inhaled Pharmaceutical Aerosols: an Introduction. Academic Press, London, UK (2001)
21. Atkins PJ. Dry powder inhalers: an overview. Respir. Care 50(10), 1304-1312 (2005) (Pubitemid 46173313)
22. Vidgren MT, Karkkainen A, Karjalainen P, Nuutinen J, Paronen TP. In vitro and in vivo deposition of drug particles inhaled from pressurised aerosol and dry powder inhaler. Drug Dev. Ind. Pharm. 14, 2649-2665 (1988)
23. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 276(5320), 1868-1871 (1997) (Pubitemid 27443665)
24. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25(12), 563-570 (2007) (Pubitemid 350138179)
25. Cheow WS, Chang MW, Hadinoto K. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm. Res. 27(8), 1597-1609 (2010)
26. Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) 6(2), 365-375 (2011).
27. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release 150(1), 49-55 (2011)
28. Takashima Y, Saito R, Nakajima A et al. Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. Int. J. Pharm. 343(1-2), 262-269 (2007) (Pubitemid 47321027)
29. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54(4), 761-766 (2004) (Pubitemid 39386728)
30. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233(1-2), 51-59 (2002) (Pubitemid 34230418)
31. Al-Hallak MH, Sarfraz MK, Azarmi S, Kohan MH, Roa WH, Lobenberg R. Microcalorimetric method to assess phagocytosis: macrophage-nanoparticle interactions. AAPS J. 13(1), 20-29 (2010)
32. Muttil P, Prego C, Garcia-Contreras L et al. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 12(3), 330-337 (2010)
33. Muttil P, Pulliam B, Garcia- Contreras L et al. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 12(4), 699-707 (2010)
34. Sung Jc, Padilla DJ, Garcia-Contreras L et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 26(8), 1847-1855 (2009)
35. Bruinenberg P, Blanchard JD, Cipolla D, Dayton F, Mudumba S, Gonda I. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. Respiratory Drug Delivery 1, 73-82 (2010)
36. Cipolla D, Redelmeier T, Eastman S, Bruinenberg P, Gonda I. Liposomes, niosomes and proniosomes-a critical update of their (commercial) development as inhaled products. Respiratory Drug Delivery 1, 41-54 (2011)
37. Carvalho TC, Peters JI, Williams RO 3rd. Influence of particle size on regional lung deposition-what evidence is there? Int. J. Pharm. 406(1-2), 1-10 (2011)
38. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl Acad. Sci. USA 99(19), 12001-12005 (2002)
39. Kabbaj M, Phillips NC. Anticancer activity of mycobacterial DNA: effect of formulation as chitosan nanoparticles. J. Drug Target 9(5), 317-328 (2001) (Pubitemid 33094551)
40. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1-2), 1-19 (2010)
41. Hinds WC. Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles. Wiley-Interscience, NY, USA (1999)
42. Kawakami K, Sumitani C, Yoshihashi Y, Yonemochi E, Terada K. Investigation of the dynamic process during spray-drying to improve aerodynamic performance of inhalation particles. Int. J. Pharm. 390(2), 250-259 (2010)
43. Kho K, Cheow WS, Lie RH, Hadinoto K. Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy. Powder Technol. 203(3), 432-439 (2010)
44. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan BHR. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind. Eng. Chem. Res. 45, 3697-3706 (2006) (Pubitemid 43812807)
45. Cheow WS, Li S, Hadinoto K. Spray drying formulation of hollow spherical aggregates of silica nanoparticles by experimental design. Chem. Eng. Res. Design 88, 673-685 (2010)
46. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RB. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int. J. Pharm. 333(1-2), 187-198 (2007) (Pubitemid 46283279)
47. Kho K, Hadinoto K. Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates. Powder Tech. 198, 354-363 (2010)
48. Hadinoto K, Cheow WS. Hollow spherical nanoparticulate aggregates as potential ultrasound contrast agent: shell thickness characterization. Drug. Dev. Ind. Pharm. 35(10), 1167-1179 (2009)
49. Kho K, Hadinoto K. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates. Colloids Surf. A Physicochem. Eng. Aspects 359, 71-81 (2010)
50. Tomoda K, Ohkoshi T, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf. B Biointerfaces 64(1), 70-76 (2008)
51. Tomoda K, Ohkoshi T, Kawai Y, Nishiwaki M, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf. B Biointerfaces 61(2), 138-144 (2008)
52. Yamamoto H, Hoshina W, Kurashima H et al. Engineering of poly(dl-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. Advanced Powder Technol. 18(2), 215-228 (2007) (Pubitemid 47181968)
53. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release 142(1), 138-145 (2009)
54. Lebhardt T, Roesler S, Uusitalo HP, Kissel T. Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation. Eur. J. Pharm. Biopharm. 78(1), 90-96 (2011)
55. Wang ZL, Finlay WH, Peppler MS, Sweeney LG. Powder formation by atmospheric spray-freeze-drying. Powder Technol. 170(1), 45-52 (2006) (Pubitemid 44715974)
56. Cheow WS, Ng ML, Kho K, Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int. J. Pharm. 404(1-2), 289-300 (2010)
57. El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J. Pharm. Sci. 98(8), 2731-2746 (2009)
58. El-Gendy N, Desai V, Berkland C. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J. Pharm. Innov. 5, 79-86 (2010)
59. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 26(7), 1752-1763 (2009)
60. El-Gendy N, Aillon Kl, Berkland C. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int. J. Pharm. 391(1-2), 305-312 (2010)
61. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int. J. Pharm. 369(1-2), 136-143 (2009)
62. Aillon KL, El-Gendy N, Dennis C, Norenberg JP, Mcdonald J, Berkland C. Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization. Mol. Pharm. 7(4), 1274-1282 (2010)
63. Tomoda K, Ohkoshi T, Hirota K et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B Biointerfaces 71(2), 177-182 (2009)
64. Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev. 61(6), 457-466 (2009)
65. Mizoe T, Ozeki T, Okada H. Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J. Control. Release 122(1), 10-15 (2007) (Pubitemid 47284548)
66. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269(2), 457-467 (2004) (Pubitemid 38045308)
67. Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J. Colloid Interface Sci. 265(2), 296-303 (2003) (Pubitemid 37072070)
68. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J. Pharm. Sci. 25(4-5), 427-437 (2005) (Pubitemid 40853870)
69. Grenha A, Seijo B, Serra C, Remunan-Lopez C. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. Biomacromolecules 8(7), 2072-2079 (2007) (Pubitemid 47104289)
70. Li X, Guo Q, Zheng X et al. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Drug Deliv. 16(3), 160-166 (2009)
71. Kaye RS, Purewal TS, Alpar HO. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. J. Pharm. Sci. 98(11), 4055-4068 (2009)
72. Ohashi K, Kabasawa T, Ozeki T, Okada H. One-step preparation of rifampicin/ poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 135(1), 19-24 (2009)
73. El-Sherbiny IM, Smyth HD. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int. J. Pharm. 395(1-2), 132-141 (2010)
74. Azarmi S, Lobenberg R, Roa WH, Tai S, Finlay WH. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev. Ind. Pharm. 34(9), 943-947 (2008)
75. Niwa T, Shimabara H, Kondo M, Danjo K. Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle. Int. J. Pharm. 382(1-2), 88-97 (2009)
76. Schiffter H, Condliffe J, Vonhoff S. Spray-freeze-drying of nanosuspensions: the manufacture of insulin particles for needle-free ballistic powder delivery. J. R. Soc. Interface 7(4), 483-500 (2010)
77. Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int. J. Pharm. 309(1-2), 178-188 (2006) (Pubitemid 43129481)
78. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 58(15), 1688-1713 (2006) (Pubitemid 44827432)
79. Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release 121(1-2), 100-109 (2007) (Pubitemid 47126070)
80. Ely L, Roa W, Finlay Wh, Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur. J. Pharm. Biopharm. 65(3), 346-353 (2007)
81. Al-Hallak MH, Azarmi S, Sun C et al. Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation. AAPS J. 12(3), 294-299 (2010)
82. Li YZ, Sun X, Gong T, Liu J, Zuo J, Zhang ZR. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid-lipid nanoparticles. Pharm. Res. 27(9), 1977-1986 (2010).